Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics, having entered the public markets through a SPAC business combination in 2018. The company develops and commercializes a portfolio of bioactive and acellular wound care products targeting chronic and surgical wound indications, placing it squarely within the healthcare and medical technology sector. On May 7, 2026, Organogenesis filed an 8-K current report with the SEC under accession number 0001661181-26-000007, disclosing a material corporate event to investors. ORGO remains an active publicly traded entity following its de-SPAC transition. For the complete filing history, ownership data, and deal analytics on ORGO and thousands of other SPAC-linked companies, sign up for full access at SpacDesk.